Alzamend Neuro Registers 98.4M Shares for Ault Lending Resale — Potential 20x Dilution

summarizeSummary

Alzamend Neuro filed an S-1 to register 98.4 million shares for resale by Ault Lending, the investor in its $25M convertible preferred stock deal. The conversion terms allow Ault Lending to convert at a deep discount, potentially increasing the share count by 20x.

check_boxKey Events · Financing and Capital Events · ALZN

• 98.4M Shares Registered for Resale

  The S-1 registers 98,388,305 shares for resale by Ault Lending, LLC, the selling stockholder in the $25M convertible preferred stock deal.

• Deep Discount Conversion Formula

  Each $1,050 preferred share converts at the greater of $0.2668 floor or 80% of the lowest closing bid price in the 5 days prior to conversion, capped at $2.00. At the floor, full conversion yields 98.4M shares.

• Potential 20x Dilution

  With only 4,825,723 shares outstanding, full conversion at the floor price would increase the share count to 103.2M — a 20x increase, massively diluting existing holders.

• Nasdaq Exchange Cap Limits Immediate Conversion

  The Nasdaq 19.99% cap restricts conversion to 964,662 shares until stockholder approval, but the registration creates a large overhang.

auto_awesomeAnalysis · ALZN · Life Sciences

This S-1 registers 98,388,305 shares for resale by Ault Lending, LLC, the affiliate that committed $25M in convertible preferred stock financing on July 31, 2026. The conversion formula — $1,050 stated value divided by the greater of $0.2668 floor or 80% of the lowest closing bid price in the 5 days prior to conversion — means Ault Lending can convert at a deep discount to market. At the floor price, the full $25M would convert into 98.4M shares, versus only 4.8M shares currently outstanding — a potential 20x increase in share count. The Nasdaq 19.99% cap limits immediate conversion to 964,662 shares until stockholder approval, but the registration itself creates a massive overhang. This is a highly dilutive financing structure for a company already facing going concern warnings and Nasdaq delisting risk.